<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170516034003N10</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-02-26</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>The effects of dry needling, shock wave therapy and corticosteroid injection in patients with tennis elbow</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of short-term and long-term effects of dry needling, shock wave therapy and corticosteroid injection on pain and sonographic findings of patients with tennis elbow: Randomized controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-01-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>68</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74447</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this research, all participants will have an equal chance of being assigned to each of the study groups. In this study, 64 patients with tennis elbow will be divided into four groups through block randomization with a block size of 8 in 8 blocks. Sequence generation was obtained through the sealed envelope site (www.sealedenvelope.com/simple-randomiser/v1/lists) as follows. Allocation concealment will be done through sealed envelopes. In this way, the obtained sequence is placed in envelopes in order. Then, for each patient who visits, the envelope that is in the selection queue is removed and if the letter A is observed, the first group intervention will be performed for the patient. If the letter B is observed, the second group intervention will be performed and similarly with the letters C and D, the third and fourth group interventions will be performed, Blinding description: The examiner and statistical analyzer  won't know anything about the kind of treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Lateral epicondylitis.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Drug therapy and the use of splints or elbow braces are considered as the usual treatment for tennis elbow. Drug treatment for all patients will be done in the form of naproxen 500 tablets, one daily for up to three weeks. The splint will allow movement of the wrist, fingers and elbow and will place the wrist in 5 degrees of extension. This splint will be used for 6 to 8 hours a day and for 4 weeks. It should be noted that due to ethical considerations, treatment will be performed in all studied groups. Intervention 2: Intervention group: Injection treatment: In this method, one milliliter of corticosteroid (Betamethasone) is injected into the common extensor tendon along with lidocaine. Intervention 3: Intervention group: dry needling: In this method, after cleaning the skin, three needles (0.25 x 50 mm) and (Tony, Stockholm, Sweden) will be inserted back and forth in the trigger points and painful tendon area. These needles are rotated 5 times and will remain in place for 10 minutes. This whole process will be repeated twice with a ten minute rest interval. After the needle is removed, the desired area is pressed with cotton to prevent bleeding. This procedure will continue for three times a week and up to ten sessions. Dry needling was performed by a skilled physiotherapist with more than ten years of experience. Intervention 4: Intervention group: shockwave therapy:shockwave therapy will be performed using a shockwave device (BTL, SWT TOPLINE UK). The parameters used will be: 10 Hz, 2000 pulses, 2-4 bar pressure. The patient will be placed in a supine position, the elbow slightly bent and the forearm pronated. The R15 shock wave therapy applicator will be placed on the most sensitive point and around it. No topical ointment will be used before the treatment. The treatment will be done two days a week for ten sessions.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Sharing is done after the end of the study. The total potential data can be shared after unidentifications of individuals.

When:
Start the access period 6 months after publicating the results

To whom:
Researchers working in universities

Conditions:
- Research that is in line with current study.
- Data correlation analysis is allowed.
-It is preferred  to have a university degree and be a researcher in the desired field.

Where to obtain:
Adress: Physiotherapy section, Block 2, , Poursina hospital, Namjoo St, Rasht. Kamran Ezzati 
Ez_kamran@yahoo.com

How to obtain:
A written request for data from the relevant university with the name and academic degree of the researcher

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Elahe Rafie</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Deputy of Research, Opposie to Azodi Stadium, Namjoo St, Rasht, Iran</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4193713194</zip>
        <telephone>+98 13 3336 2639</telephone>
        <email>Research@gums.ac.ir</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Kamran Ezzati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Central Office of Guilan University of Medical Sciences, Parastar St., Rasht, I.R. Iran</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4193713194</zip>
        <telephone>+98 13 3369 0099</telephone>
        <email>kamranezzati@gums.ac.ir</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Visual analogue scale (VAS) score of 3 or more
Pain in the lateral epicondyle region of the elbow, which increases when palpating the external tendons.</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>55 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>People with neuropathy such as thyroid problems.
People with neck and shoulder myopathy.
People with a history of neck and shoulder, elbow and wrist surgery.
People with cancer, infection, pain and lung disease, acquired immunodeficiency virus.
People with psychosocial disorders who were evaluated using the Persian version of the DASS-21 stress-anxiety-depression questionnaire and obtained scores above the normal range. (Normal scores: maximum 9= depression, maximum 7 = anxiety, maximum 14 = stress)
Patients with osteochondritis of lateral epicondyle, osteoarthritis of the lateral compartment of the elbow, varus instability and the presence of radial tunnel syndrome.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M77.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Lateral epicondylitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Drug therapy and the use of splints or elbow braces are considered as the usual treatment for tennis elbow. Drug treatment for all patients will be done in the form of naproxen 500 tablets, one daily for up to three weeks. The splint will allow movement of the wrist, fingers and elbow and will place the wrist in 5 degrees of extension. This splint will be used for 6 to 8 hours a day and for 4 weeks. It should be noted that due to ethical considerations, treatment will be performed in all studied groups.</i_keyword>
      <i_keyword>Intervention group: Injection treatment: In this method, one milliliter of corticosteroid (Betamethasone) is injected into the common extensor tendon along with lidocaine.</i_keyword>
      <i_keyword>Intervention group: dry needling: In this method, after cleaning the skin, three needles (0.25 x 50 mm) and (Tony, Stockholm, Sweden) will be inserted back and forth in the trigger points and painful tendon area. These needles are rotated 5 times and will remain in place for 10 minutes. This whole process will be repeated twice with a ten minute rest interval. After the needle is removed, the desired area is pressed with cotton to prevent bleeding. This procedure will continue for three times a week and up to ten sessions. Dry needling was performed by a skilled physiotherapist with more than ten years of experience</i_keyword>
      <i_keyword>Intervention group: shockwave therapy:shockwave therapy will be performed using a shockwave device (BTL, SWT TOPLINE UK). The parameters used will be: 10 Hz, 2000 pulses, 2-4 bar pressure. The patient will be placed in a supine position, the elbow slightly bent and the forearm pronated. The R15 shock wave therapy applicator will be placed on the most sensitive point and around it. No topical ointment will be used before the treatment. The treatment will be done two days a week for ten sessions</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: Before intervention, After treatments, 3 month follow-up. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Echogenicity intensity. Timepoint: Before intervention, After treatments, 3 month follow-up. Method of measurement: Using ultrasonography.</sec_outcome>
      <sec_outcome>Common extensor tendon thickness. Timepoint: Before intervention, After treatments, 3 month follow-up. Method of measurement: Using ultrasonography.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-06-14</approval_date>
        <contact_name>Ethics committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>5th floor, Central office of Guilan University of Medical Sciences, Namjoo St., Rasht, Iran Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
